论文部分内容阅读
目的:探讨检测点激酶2(check point kinase2,Chk2)和重构剪切因子1(remodeling and spacing factor1,Rsf1)在卵巢浆液性腺癌(ovarian serous adenocarcinoma,OSA)中表达及其临床意义。方法:采用免疫组化SP法检测58例高级别OSA、14例低级别OSA中Chk2和Rsf1蛋白的表达水平,分析与临床病理参数的关系。并检测27例卵巢交界性浆液性肿瘤(ovarian borderline serous tumor,OBST)中两种蛋白的表达水平,与OSA进行对比分析。结果:Chk2在高级别和低级别OSA中阳性率分别为79.3%(46/58)和50.0%(7/14),差异有统计学意义,χ2=4.99,P=0.026;在OSA和OBST中阳性率分别为77.8%(56/72)和44.4%(12/27),差异有统计学意义,χ2=7.41,P=0.006。Chk2的表达与OSA复发及3年生存期有相关性,P<0.05;而与年龄、肿瘤最大径、淋巴结有无转移、发病部位及pTNM分期无关,P>0.05。Rsf1在高级别和低级别OSA中阳性率分别为86.2%(50/58)和57.1%(8/14),差异有统计学意义,χ2=6.08,P=0.023;在OSA及OBST中阳性率分别为79.2%(57/72)和51.9%(14/27),差异有统计学意义,χ2=8.16,P=0.004。Rsf1的表达与OSA复发及pTNM分期有相关性,P<0.05;而与年龄、肿瘤大小、淋巴结有无转移、发病部位及3年生存期无关,P>0.05。Chk2和Rsf1的表达存在明显相关性,r=0.343,P=0.003。结论:Chk2与Rsf1在OSA的发生发展中起重要作用,可作为临床指导治疗和评价患者预后的重要标志。
Objective: To investigate the expression of checkpoint kinase 2 (Chk2) and remodeling factor 1 (Rsf1) in ovarian serous adenocarcinoma (OSA) and its clinical significance. Methods: The expressions of Chk2 and Rsf1 protein in 58 cases of high grade OSA and 14 cases of low grade OSA were detected by immunohistochemical SP method. The relationship between them and clinical and pathological parameters was analyzed. The expression of two proteins in 27 ovarian borderline serous tumor (OBST) was detected and compared with OSA. Results: The positive rates of Chk2 in high grade and low grade OSA were 79.3% (46/58) and 50.0% (7/14) respectively, the difference was statistically significant (χ2 = 4.99, P = 0.026). In OSA and OBST The positive rates were 77.8% (56/72) and 44.4% (12/27) respectively, the difference was statistically significant (χ2 = 7.41, P = 0.006). The expression of Chk2 was correlated with OSA recurrence and 3-year survival (P <0.05), but not with age, tumor diameter, lymph node metastasis, disease location and pTNM stage (P> 0.05). The positive rates of Rsf1 in high grade and low grade OSA were 86.2% (50/58) and 57.1% (8/14) respectively, the difference was statistically significant (χ2 = 6.08, P = 0.023). The positive rates of Rsf1 in OSA and OBST 79.2% (57/72) and 51.9% (14/27) respectively, the difference was statistically significant (χ2 = 8.16, P = 0.004). There was a correlation between the expression of Rsf1 and the recurrence of OSA and the stage of pTNM (P <0.05), but not with age, tumor size, lymph node metastasis, disease site and 3-year survival. Chk2 and Rsf1 expression was significantly correlated, r = 0.343, P = 0.003. Conclusion: Chk2 and Rsf1 play an important role in the development of OSA. They may serve as an important marker for clinical treatment and evaluation of the prognosis of patients.